International Stem Cell reports interim Phase I data for PD stem cell treatment

International Stem Cell Corp. (OTCQB:ISCO) reported interim 6-month data from the first cohort of patients in a Phase I trial to treat Parkinson's disease showing that

Read the full 269 word article

User Sign In